Izabella Tyszler
VP, Marketing & Field Execution
Orphazyme
Rare Disease Launch Specialist
Izzy Tyszler has dedicated her career to launching campaigns for rare disease patients. She has overseen more than seven rare and orphan disease launches and, more importantly, demonstrated a deep compassion for the patients and their caregivers living with these life-changing diseases.
Izzy began her career at Lundbeck, where she focused on managing projects for global alliance management, marketing strategy, and launch execution for rare diseases in CNS. Turning next to treating Duchene Muscular Dystrophy (DMD), Izzy transitioned to Marathon Pharmaceuticals where she provided leadership for pre-launch planning for Emflaza. Always mindful of the patient/caregiver experiences, Izzy reviewed patient journey research and engaged with customers to develop tailored patient and caregiver services.
Izzy continued to trailblaze in rare disease work while directing product relaunch strategies and activities for Kynamro at Kastle Pharmaceuticals. Along with leading marketing, sales training, and market access initiatives with a startup field team of eight specialty managers, Izzy helped train specialty pharmacy clinical nurse educators to help bridge the gap between treatment and patient. The next stop in her career was AveXis (now Novartis Gene Therapies), where she launched Zolgensma, the first gene therapy product for pediatric patients under 2-years-old who are living with a rare neurological genetic disorder, spinal muscular atrophy (SMA). As part of the launch effort, Izzy spearheaded U.S. launch readiness across the entire organization for the company’s first commercial approval.
Currently at Orphazyme, Izzy is working on the company’s first U.S. product launch that will benefit patients living with a rare lysosomal disorder that does not currently have an approved treatment. Beyond bringing the treatment to market, Izzy participates in rare disease day rallies, walks, and other awareness projects to help elevate those who might not otherwise have a voice.
Co-worker Mark Meier endorses her commitment not only to therapies, but also to patients, “I have worked with Izzy across three different pharmaceutical companies and have consistently witnessed her passion to assure that patients with rare diseases not only have approved treatments, but also the important resources they, and their caregivers, need to understand and manage their disease.”
